© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL) stock surged +0.33%, trading at $25.59 on NASDAQ, up from the previous close of $25.51. The stock opened at $25.54, fluctuating between $25.49 and $25.59 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | 25.54 | 25.59 | 25.49 | 25.59 | 1.98K |
| Sep 10, 2026 | 25.52 | 25.53 | 25.47 | 25.50 | 7.41K |
| Sep 09, 2026 | 25.50 | 25.54 | 25.50 | 25.54 | 4.08K |
| Sep 08, 2026 | 25.49 | 25.51 | 25.47 | 25.49 | 6.86K |
| Sep 04, 2026 | 25.52 | 25.56 | 25.48 | 25.56 | 3.21K |
| Sep 03, 2026 | 25.48 | 25.48 | 25.44 | 25.44 | 0 |
| Sep 02, 2026 | 25.48 | 25.48 | 25.45 | 25.46 | 1.48K |
| Sep 01, 2026 | 25.47 | 25.48 | 25.47 | 25.48 | 228 |
| Aug 31, 2026 | 25.48 | 25.48 | 25.44 | 25.44 | 734 |
| Aug 28, 2026 | 25.45 | 25.48 | 25.41 | 25.42 | 2.34K |
| Aug 27, 2026 | 25.45 | 25.45 | 25.42 | 25.42 | 1.58K |
| Aug 26, 2026 | 25.45 | 25.45 | 25.44 | 25.44 | 1.49K |
| Aug 25, 2026 | 25.43 | 25.45 | 25.43 | 25.45 | 625 |
| Aug 24, 2026 | 25.44 | 25.44 | 25.42 | 25.43 | 618 |
| Aug 21, 2026 | 25.45 | 25.45 | 25.42 | 25.42 | 293 |
| Aug 20, 2026 | 25.45 | 25.45 | 25.45 | 25.45 | 1.38K |
| Aug 19, 2026 | 25.44 | 25.44 | 25.44 | 25.44 | 826 |
| Aug 18, 2026 | 25.46 | 25.46 | 25.41 | 25.41 | 2.15K |
| Aug 17, 2026 | 25.46 | 25.46 | 25.40 | 25.43 | 1.59K |
| Aug 14, 2026 | 25.46 | 25.46 | 25.40 | 25.40 | 335 |
SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.
| Employees | 24 |
| Beta | 0.06 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0.499% |
| Fiscal Year Ends | N/A |
| Sector | Financial Services |
| Industry | Financial - Credit Services |